HK2 and prostate cancer: High expression of HNF4A, HK2, or SLC2A1 was associated with poor survival of patients with NB, breast cancer, colon cancer, glioblastoma, lung cancer, ovarian cancer, or prostate cancer (Additional file 1: Figure S2e and Figure S3).